Clinical trials: Helicobacter
Helicobacter Pylori Infection
A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients
This study compared efficacy and safety of basic triple therapy according to treatment period. This study evaluated Effect of CYP2C19 genetic polymorphisms on the efficacy
- Trial name
- NCT03099876
- Testing
- treatment period
- Where
- 4 sites in South Korea
- Volunteers
- 320 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Helicobacter Pylori Infection, Dyspepsia
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H.
- Trial name
- ERADICATE Hp2 (NCT03198507)
- Testing
- RHB-105, Active Comparator
- Where
- 55 sites in United States
- Volunteers
- 455 people
- Sponsor
- RedHill Biopharma Limited
Helicobacter Pylori Infected Subjects, Helicobacter Pylori Naive Subjects
Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers
A Phase 1, multi-center, randomised, double-blind and adjuvant-controlled study to evaluate the safety, tolerability, and efficacy of IMX101 in H. pylori-negative and H. pylori-infected healthy volunteers.
- Trial name
- IMX-02 (NCT03270800)
- Testing
- CTA control, IMX101 vaccine
- Where
- 2 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- ImevaX
Helicobacter Infections
Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
This study compared efficacy and safety of basic triple therapy including Ilaprazole 10mg, Levofloxacin 500mg and Amoxicillin 1000mg BID for 10 days on the first line eradication treatment of H.pylori
- Trial name
- NCT02352701
- Testing
- Noltec tab. 10mg, Chongkundang Amoxicillin Cap. 500mg, Cravit Tab. 500mg
- Where
- South Korea
- Volunteers
- 320 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Helicobacter Infections
Specimen Collection Study for H. Pylori Testing
The objective of this study is to acquire human specimens from subjects undergoing routine endoscopy with gastric biopsy for the diagnosis of active H. pylori infection.
- Trial name
- NCT02970110
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Biomerica
Helicobacter Pylori Infection
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
This is a single center, open label, drug-drug interaction, Phase 1 study of TNP-2198 in approximately 32 healthy participants, includes 2 cohorts (16 participants per cohort): Midazolam cohort and Clarithromycin cohort.
- Trial name
- NCT06551623
- Testing
- Midazolam, Clarithromycin, TNP-2198
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Inc.
HELICOBACTER INFECTION
Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
Helicobator pylori (H. pylori) is a bacteria which survives in the lining of the stomach. An estimated 50% of the world's population is infected with H. pylori.
- Trial name
- NCT02051348
- Testing
- Pylopass
- Where
- Ireland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
Gram-Negative Bacterial Infections, Helicobacter Infections
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole.
- Conditions
- Gram-Negative Bacterial Infections, Helicobacter Infections, Dyspepsia
- Trial name
- FLASH (NCT00723502)
- Testing
- Finafloxacin + Amoxicillin, Finafloxacin + Esomeprazole
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- MerLion Pharmaceuticals GmbH
Helicobacter Pylori Infection
Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
This study is a multicenter, randomized, double-blind, double-dummy, phase III study to evaluate the efficacy and safety of tegoprazan versus esomeprazole-containing bismuth quadruple therapy in patients infected with…
- Trial name
- NCT05577468
- Testing
- Tegoprazan
- Where
- China
- Volunteers
- 561 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Erosive Esophagitis, Heartburn
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
The main objective of the study is to compare the maternal, fetal, and infant outcomes of pregnant women who are exposed to vonoprazan during pregnancy with outcomes of an internal comparison cohort of pregnant women who are…
- Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Helicobacter Pylori Infection
- Trial name
- NCT06660342
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Helicobacter Pylori Infection
Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori
At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in…
- Trial name
- NCT01109381
- Testing
- GT08
- Where
- Singapore
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synergy Pharmaceuticals Pte. Ltd.
HELICOBACTER PYLORI INFECTIONS
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple…
- Trial name
- NCT07606833
- Testing
- Anaprazole Sodium enteric-coated tablet, Esomeprazole magnesium enteric-coated tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Helicobacter Infected Patients
Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial
The purpose of this study is to improve first line Helicobacter pylori eradication rate and to compare the sequential versus conventional triple therapy.
- Trial name
- NCT01418300
- Testing
- sequential versus triple
- Where
- South Korea
- Volunteers
- 159 people
- Sponsor
- Jun-Won Chung
Helicobacter Pylori Infection
Evaluation of SQ109 Plus PPI in Urea Breath Test-Positive Volunteers
Helicobacter pylori infection of the gastric epithelium is the most common bacterial infection worldwide. Its global prevalence is estimated at 50%, though the burden falls disproportionately on the developing world, where the…
- Trial name
- NCT01252108
- Testing
- SQ109
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Helicobacter Pylori Infection, Gastric Ulcer
Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects
The primary objective is to obtain stool samples from post-therapy subjects already undergoing evaluation for an H. pylori infection by upper esophagogastroduodenoscopy (EGD) and gastric biopsy.
- Conditions
- Helicobacter Pylori Infection, Gastric Ulcer, Nausea, Abdominal Pain
- Trial name
- NCT03060733
- Testing
- Post-Therapy
- Where
- 5 sites in United States, Italy
- Volunteers
- 13 people
- Sponsor
- DiaSorin Inc.
H. Pylori Eradication Therapy
Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects
This study aims to evaluate the Efficacy and Safety of JP-1366-based Triple-Therapy in H. pylori-positive Subjects
- Trial name
- NCT07875933
- Volunteers
- 414 people
- Sponsor
- Onconic Therapeutics Inc.
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics
Clinical Study to Confirm Safety and Accuracy in Detection of H. pylori with 13C-Urea Breath Test using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population
- Trial name
- NCT02905825
- Testing
- BreathID® Hp System, BreathID® Hp Lab System, Stool Test
- Where
- 6 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Meridian Bioscience, Inc.
Helicobacter Pylori
A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection
The purpose of this study is to evaluate the efficacy of helicobacter pylori (HP) eradication with bismuth-containing quadruple therapy with vonoprazan versus esomeprazole in all HP-positive participants.
- Trial name
- NCT04198363
- Testing
- Vonoprazan, Amoxicillin, Clarithromycin
- Where
- 29 sites in China
- Volunteers
- 510 people
- Sponsor
- Takeda
Helicobacter Pylori Eradication Antibiotic
Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection
This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID…
- Trial name
- NCT02835560
- Testing
- Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy, Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
- Volunteers
- 100 people
- Sponsor
- Livzon Pharmaceutical Group Inc.